This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In the EU, a joint PFAS Restriction Proposal under REACH was submitted, aiming for a full ban by 2028/2030. These chemicals are everywhere and have been used in many ways over the decades, bringing a range of benefits from water- and stain-resistant coatings and firefighting foams to nail polish and food packaging.
GlobalData predicts the axSpA market across the seven major pharmaceutical markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) will reach $3.6bn by 2028. Jyseleca in third development partnership The development of Jyseleca has seen several shifts in the pharmaceutical industry.
24 The EU will also be investing $600 billion in the US and purchasing $750 billion worth of US energy exports through the year 2028. July 27 - Trump reached a formal trade agreement with the European Union in which a maximum 15% levy will be imposed on “most” EU exports, including autos and their parts; semiconductors; and pharmaceuticals.
The first tranche will be received by Revolution, following US Food and Drug Administration (FDA) approval of daraxonrasib to treat metastatic PDAC by January 2028. The debt facility portion consists of three tranches totalling up to $750m linked directly to daraxonrasib’s commercial milestones. Sign up for our daily news round-up!
Keytruda, which brought in $30bn in revenue in 2024, is approaching patent expirations set in 2028, and Merck is therefore intensifying efforts to restructure its portfolio, according to a report by Reuters. How will RFK Jr’s American dream for vaccines play out? Give your business an edge with our leading industry insights.
billion and an additional $2 billion in non-contingent anniversary payments through 2028. This news comes just 10 days after BioNTech announced a global co-development and co-commercialization agreement valued at up to $11.1 billion for BNT327 (2). Under that deal, BMS will provide BioNTech with an upfront payment of $1.5 References 1.
Astria anticipates that its cash, cash equivalents and short-term investments will fund its current operating plan into 2028. Kaken will support the ALPHA-ORBIT Phase 3 trial in Japan and handle regulatory submissions. Give your business an edge with our leading industry insights.
With biosimilars projected to enter the market by 2028, revenues from the branded drug are likely to face sharp declines – consistent with historical trends. Sales for the cancer drug grew 9% in Q2 on the back of further indication approvals – its $8bn in sales accounted for more than half of the company’s revenue.
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? billion by 2028, according to projections from GlobalData, the integration of real-world data (RWD) has become essential for producing meaningful insights that can drive measurable improvements in patient outcomes.
Without removing the current members, the current Trump administration would not have been able to appoint a majority of new members until 2028, RFK Jr wrote. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard.
With GlobalData currently forecasting that the data and analytics market in pharma will reach $2.1bn by 2028, real-world data is becoming essential to healthcare research. With the data and analytics market in pharmaceuticals now set to be worth $2.1bn by 2028, data needs to be integrated meaningfully to change healthcare outcomes.
Europe’s pharmaceutical packaging and labelling market is projected to reach $35.78 billion in 2028, according to a report by Arizton. billion in 2022, the pharmaceutical packaging and labelling market in Europe is expected to expand at a compound annual growth rate (CAGR) of 4.78 percent up to 2028. percent in 2022.
The workplan, which runs until 2028, will help the European medicines regulatory network (EMRN) embrace the opportunities of AI for personal productivity, automating processes and systems, increasing insights into data and supporting more robust decision-making to benefit public and animal health.
These activities are expected to be completed incrementally between 2026 to 2028, the company stated. Novo Nordisk declared that it will help to boost its global capacity, “from manufacturing of active pharmaceutical ingredients (API) through to packaging.” Construction has already begun.
Transfer pricing proposal As part of the EC’s package of initiatives to reduce tax compliance costs, there is a proposal specifically aimed at harmonising transfer pricing rules in the EU. SMEs are also set to benefit, although the rules will be discretionary.
billion in 2028. While the drug was granted accelerated approval in June 2019, it did not deliver on a key overall survival (OS) endpoint as part of its post-marketing data package. In 2022, the company reported Keytuda sales of $20.9 billion in its FY 2022 results. GlobalData is the parent company of Pharmaceutical Technology.
Launch of the EU pharmaceutical package The European Commission plans to commence initiatives relating to the European Pharmaceutical Strategy (strategy) with the publication of the revised EU pharmaceutical package scheduled during the first quarter of 2023. of the MDR and Article 110.4
This calls for celebration with a cup of stimulation, and we are opening a new package of pecan pie for the occasion. In a press release issued ahead of an investor meeting today, the company also said it plans to break even by 2028, when it expects it will reach annual sales of $6 billion. Sound familiar?
In response to supply chain challenges, including shortages of critical glass vials for products like COVID-19 vaccines and parenteral drugs, the Packaging and Distribution Expert Committee (PD EC) has made a significant revision of United States Pharmacopeia (USP) General Chapter <660>—Glass.
These new results reinforce our differentiating data package for PDC*lung01. After the completion of the current clinical study with PDC*lung01 (PDC-LUNG-101), we plan to conduct a randomized, open-label phase 2 clinical trial with PDC*lung in the B2 cohort setting (2025 to 2028).
This labeling requirement will apply to packages “developed or copyrighted” from January 1, 2027 onward. The QR codes and digital disclosures must be included on the outer product packaging by January 1, 2028. The law applies to all foods, even if produced outside of the state. Preservatives such as BHA and BHT. Synthetic dyes.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content